Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Matthew Memoli · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $123,282 — The SARS-COV-2 virus has had a major impact on morbidity and mortality worldwide, as well as having devastating global economic and societal impact. The overall impact cannot be quantified, some of which is due to the worldwide public health response and not the virus itself. Knowledge of the anti…
Catharine Bosio · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $269,478 — Pulmonary infections represent 5 of the 30 most common causes of death around the world, with lower respiratory infections resulting on average of 4 million deaths each year and the leading cause of death among children under the age of 5. We are currently in the midst of a pandemic caused by the pu…
Vincent Munster · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $357,333 — The research program of the Virus Ecology Section (VES) is focused at understanding the drivers of virus emergence. Upon the emergence of SARS-CoV-2 in 2019, the research we swiftly pivoted to SARS-CoV-2. We were the first was to establish ACE2 as the SARS-CoV-2 receptor and rapidly developed a no…
Ottavia Delmonte · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $111,089 — During the Fiscal Year 2024 (October 23- August 24) I obtained the following results: A) Molecular and cellular characterization of novel genetic defects leading to IEI. This collaborative effort with scientist at the Imagine Institute in Paris (France) allowed us to describe a novel IEI due to mu…
Kaitlyn Sadtler · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · 2024 · $873,333 — Finalizing SARS-CoV-2 Research We are finalizing the publication of our last works on COVID19 research which have all completed experimentation and are being prepared for submission to scientific journals. Please refer to prior report regarding COVID19 research projects. Biomaterials and Immunoeng…
Manas Ray · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2024 · $1,566,921 — The NIEHS Gene Editing and Mouse Model (GEMM) core is a service orientated facility, which aims at helping investigators at the NIEHS to develop animal models to further their research and fulfilling the mission statement of NIEHS. The GEMM core aids investigators in generating transgenic mouse mode…
Jason Williams · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2024 · $3,081,019 — A variety of service and collaborative projects for mass spectrometry analyses have been or are being carried out within the Mass Spectrometry Research and Support Group with approximately 3000 samples analyzed from about 40 scientists representing about 25 principal investigators or core heads from…
Behdad Afzali · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2024 · $2,757,763 — In the past years we had shown that cell-autonomous Complement is produced both from immune and non-immune cells and delineated the major pathways of their induction, notably LFA-induced signals in T cells and type I interferons in respiratory epithelial cells. These findings were important because …
Xin Xu · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2024 · $5,131,109 — The DMPK Lab was initially established within the Therapeutic Development Branch in the Division of Preclinical Innovation (DPI) in 2011. It became the DMPK Core in Oct 2021. The mission of the DMPK Core is to address issues related to drug absorption, biodistribution and elimination via metabolis…
Marc Ferrer · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2024 · $85,450 — We have established protocols for culturing primary human small airway epithelial cells and alveolar cells in a transwell air-liquid-interface (ALI) model. Tissue biofabrication has been optimized in a 96-well plate format, including the formation of a microvessel network. We are positioning these…
Steven Holland · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $19,619 — For Autoantibody study, patient samples from the COVID-19 cohort obtained by Dr. Notarangelo, and control samples, were comprehensively screened for the presence of anticytokine autoantibodies. Functional studies were also performed to verify if positive samples contained neutralizing antibodies. We…
David Kurtz · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2024 · $2,300,332 — The Quality Assurance Laboratory (QAL) in the Comparative Medicine Branch at the National Institute of Environmental Health Science (NIEHS)performs testing on the microbiological and/or chemical contamination of critical aspects of the overall NIEHS research program. Our primary task is monitoring …
Tongqing Zhou · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,554,806 — Highly effective neutralizing antibodies could have utility in the prevention or treatment of infection from HIV-1, influenza virus, Lassa virus, and other human pathogens, including the recently emerged SARS-CoV-2. Much of our work with neutralizing antibodies has focused on identifying, characteri…
Daniel Cesar Douek · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $912,355 — In this project we use next generation sequencing approaches to sequence the adaptive immune receptors of antigen-specific B cells and T cells. The sequencing is increasingly at the single cell level and paired with whole transcriptome analysis. We do this in the context of vaccination, natural infe…
Masaru Kanekiyo · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,272,981 — Our previous work has led to the development of vaccines against respiratory syncytial virus and Zika that have reached late phase clinical testing. While we are still performing exploratory studies on immune responses to RSV in humans, our work on emerging and resurgent viruses has shifted to focus…
Sarah Andrews · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $6,981,494 — The Vaccine Immunology Program is responsible for the end point analyses of clinical vaccine, therapeutic and prevention trials carried out by the Vaccine Research Center and collaborates with intramural and extramural investigators. In addition, the VIP investigates basic B cell immunobiology to el…
Daniel Cesar Douek · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $153,089 — In this project we use next generation sequencing approaches to sequence the adaptive immune receptors of SARS-CoV-2-specific adaptive immune responses in infected and/or vaccinated humans and non-human primates. The sequencing is increasingly at the single cell level and paired with whole transcrip…
Mario Roederer · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,037,303 — For norovirus, we identified a strain that successfully infects NHP. This model is now being tested in vaccine and monoclonal antibody therapies to see if it can predict human uses. We will also test therapeutics. For WEVEE, we have isolated almost 100 distinct nonhuman primate monoclonal antibod…
Wing Pui Kong · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,368,169 — Since there is no effective cure for COVID-19. Though the mRNA vaccines were authorized for emergency use, the durability of protection provided by these two mRNA vaccines is still a concern, given the fact that the spike-specific antibodies decline rapidly in convalescent sera of COVID patients. Du…
Sanchita Das · CLINICAL CENTER · 2024 — Detection of variants is important in understanding the epidemiology of viral infections and has been very significant in the COVID-19 pandemic. Persistent viral replication in immunocompromised patients is likely the result of profound lymphocyte defects due to B- and T-cell depleting therapies or …